Welcome to our dedicated page for Biolinerx news (Ticker: BLRX), a resource for investors and traders seeking the latest updates and insights on Biolinerx stock.
BioLineRx Ltd (NASDAQ/TASE: BLRX) is a clinical-stage biopharmaceutical company advancing innovative therapies in oncology and rare diseases, including its FDA-approved stem cell mobilizer APHEXDA®. This page provides centralized access to official company announcements, clinical trial updates, and strategic partnership developments.
Investors and researchers will find verified updates on pipeline progress, regulatory milestones, and operational initiatives. Content includes earnings reports, clinical data publications, licensing agreements, and manufacturing updates, all sourced directly from BioLineRx communications.
Regularly refreshed with new developments, this resource enables stakeholders to track the company’s work in areas like multiple myeloma treatment optimization and sickle cell disease gene therapy research. Bookmark this page for efficient monitoring of BLRX’s advancements in targeted drug development and commercialization strategies.
BioLineRx (NASDAQ: BLRX) has received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share for 30 consecutive trading days. This does not immediately affect the company's listing or trading on Nasdaq. BioLineRx has until November 11, 2024, to regain compliance by maintaining a bid price of at least $1.00 for 10 consecutive business days. If unsuccessful, an additional 180-day compliance period may be granted, provided other listing standards are met. The company's operations remain unaffected, and its shares continue to trade on the Tel Aviv Stock Exchange.
BioLineRx presented new economic model data for APHEXDA (motixafortide) for CD34+ hematopoietic stem cell mobilization in patients with multiple myeloma at the ISPOR 2024 conference. The data compared costs and healthcare resource utilization for patients undergoing autologous stem cell transplantation, highlighting potential benefits of using APHEXDA in reducing the need for multiple apheresis sessions.
FAQ
What is the current stock price of Biolinerx (BLRX)?
What is the market cap of Biolinerx (BLRX)?
